Panama7/iStock Editorial via Getty Images
- Sanofi (NASDAQ:SNY) announces an equity investment of $180M and a new strategic collaboration with Owkin comprised of discovery and development programs in four exclusive types of cancer, with a total payment of $90M for three years plus additional research milestone-based payments.
- Owkin is a French American startup that specializes in artificial intelligence and federated learning for medical research.
- This collaboration will support Sanofi’s growing oncology portfolio in core areas such as lung cancer, breast cancer and multiple myeloma.
- Sanofi will leverage the comprehensive Owkin Platform, in order to find new biomarkers and therapeutic targets, building prognostic models, and predicting response to treatment from multimodal patient data.